Brian C. Healy

Brian C. Healy

Auto-generated profile, based on publicly available information

Brian C. Healy

Department of Neurology, Mass General Brigham, Boston, MA, 02115, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in Science
Verified
Journal Article
Closed access
KBKjetil Bjornevik
Kjetil Bjornevik
MCMarianna Cortese
Marianna Cortese
BHBrian C. Healy
Brian C. Healy
JKJens Kuhle
Jens Kuhle
MMMichael Mina
Michael Mina
AAAlberto Ascherio
Alberto Ascherio
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system of unknown etiology. We tested the hypothesis that MS is caused by Epstein-Barr virus (EBV) in a cohort comprising more than 10 million young adults on active duty in the US military, 955 of whom were diagnosed with MS during their period of service. Risk of MS increased 32-fold after infection with EBV but was not increased after infection with other viruses, including the similarly transmitted cytomegalovirus. Serum levels of neurofilament light chain, a biomarker of neuroaxonal degeneration, increased only after EBV seroconversion. These findings cannot be explained by any known risk factor for MS and suggest EBV as the leading cause of MS.

12 February 2019 in BMC Neurology
Verified
Journal Article
Open access
PDF file
CHChristopher C. Hemond
Christopher C. Hemond
BGBonnie I. Glanz
Bonnie I. Glanz
RBRohit Bakshi
Rohit Bakshi
TCTanuja Chitnis
Tanuja Chitnis
BHBrian C. Healy
Brian C. Healy
Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine; recent evidence shows correlation with psychological parameters as well. Objectives/Aims: To characterize clinical, neuroimaging, and psycho-neuro-immunological associations with NLR and MLR in persons with multiple sclerosis (MS). We identified a large cohort of clinically well-defined patients from our longitudinal database that included MS-related outcomes, disease-modifying therapy, patient-reported outcome (PRO) measures, and quantified cerebral MRI at 1.5 T. We queried hospital records for complete blood counts within 2 months of each clinic visit and excluded those obtained during clinical relapses. Four hundred eighty-three patients, with a mean of 3 longitudinal observations each, were identified who met these criteria. Initial analyses assessed the association between NLR and MLR as the outcomes, and psychological and demographic predictors in univariable and multivariable models controlling for age, gender and treatment. The second set of analyses assessed the association between clinical and MRI outcomes including whole brain atrophy and T2-hyperintense lesion volume, with NLR and MLR as predictors in univariable and multivariable models. All analyses used a mixed effects linear or logistic regression model with repeated measures. Unadjusted analyses demonstrated significant associations between higher (log-transformed) NLR (but not MLR) and PRO measures including increasing depression (p = 0.01), fatigue (p < 0.01), and decreased physical quality of life (p < 0.01). Higher NLR and MLR strongly predicted increased MS-related disability as assessed by the Expanded Disability Status Scale, independent of all demographic, clinical, treatment-related, and psychosocial variables (p < 0.001). Lastly, higher NLR and MLR significantly discriminated progressive from relapsing status (p ≤ 0.01 for both), and higher MLR correlated with increased whole-brain atrophy (p < 0.05) but not T2 hyperintense lesion volume (p > 0.05) even after controlling for all clinical and demographic covariates. Sensitivity analyses using a subset of untreated patients (N = 146) corroborated these results. Elevated NLR and MLR may represent hematopoetic bias toward increased production and pro-inflammatory priming of the myeloid innate immune system (numerator) in conjunction with dysregulated adaptive immune processes (denominator), and consequently reflect a complementary and independent marker for severity of MS-related neurological disability and MRI outcomes.

1 January 2020 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
DSDiana M. Smith
Diana M. Smith
LDLaura Duque
Laura Duque
JHJeff C. Huffman
Jeff C. Huffman
BHBrian C. Healy
Brian C. Healy
CCChristopher M. Celano
Christopher M. Celano

1 November 2020 in Journal of Psychosomatic Research
Verified
Journal Article
Closed access
ARAdrianna Ratajska
Adrianna Ratajska
BGBonnie I. Glanz
Bonnie I. Glanz
TCTanuja Chitnis
Tanuja Chitnis
HWHoward L. Weiner
Howard L. Weiner
BHBrian C. Healy
Brian C. Healy

16 May 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MFMai Fujiwara
Mai Fujiwara
RSRadhika Raheja Suresh
Radhika Raheja Suresh
LGLucien P. Garo
Lucien P. Garo
AAAmrendra K Ajay
Amrendra K Ajay
RKRyoko Kadowaki-Saga
Ryoko Kadowaki-Saga
Gopal MurugaiyanGopal Murugaiyan
Gopal Murugaiyan
A disequilibrium between immunosuppressive Tregs and inflammatory IL-17–producing Th17 cells is a hallmark of autoimmune diseases, including multiple sclerosis (MS). However, the molecular mechanisms underlying the Treg and Th17 imbalance in CNS autoimmunity remain largely unclear. Identifying the factors that drive this imbalance is of high clinical interest. Here, we report a major disease-promoting role for microRNA-92a (miR-92a) in CNS autoimmunity. miR-92a was elevated in experimental autoimmune encephalomyelitis (EAE), and its loss attenuated EAE. Mechanistically, miR-92a mediated EAE susceptibility in a T cell–intrinsic manner by restricting Treg induction and suppressive capacity, while supporting Th17 responses, by directly repressing the transcription factor Foxo1. Although miR-92a did not directly alter Th1 differentiation, it appeared to indirectly promote Th1 cells by inhibiting Treg responses. Correspondingly, miR-92a inhibitor therapy ameliorated EAE by concomitantly boosting Treg responses and dampening inflammatory T cell responses. Analogous to our findings in mice, miR-92a was elevated in CD4 + T cells from patients with MS, and miR-92a silencing in patients’ T cells promoted Treg development but limited Th17 differentiation. Together, our results demonstrate that miR-92a drives CNS autoimmunity by sustaining the Treg/Th17 imbalance and implicate miR-92a as a potential therapeutic target for MS.

4 May 2022 in Annals of Neurology
Verified
Journal Article
Closed access
GBGauruv Bose
Gauruv Bose
BHBrian C. Healy
Brian C. Healy
HLHrishikesh A. Lokhande
Hrishikesh A. Lokhande
Marinos SotiropoulosMarinos Sotiropoulos
Marinos Sotiropoulos
MPMariann Polgar‐Turcsanyi
Mariann Polgar‐Turcsanyi
TCTanuja Chitnis
Tanuja Chitnis